文献速递前列腺癌

前列腺切除术后放疗的中间终点:5年远处转移预测总生存

Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival.
PubMed 文献 · Eur Urol · 2018-01-03

多中心回顾性研究纳入566例前列腺切除术后放疗(PORT)男性,中位随访8.2年,评估生化失败(BF)、远处转移(DM)和去势抵抗性前列腺癌(CRPC)与总生存(OS)的相关性。时间依赖模型显示BF(HR 2.32)、DM(HR 6.52)、CRPC(HR 2.47)均与OS相关;5年DM的c指数最高(0.78),对OS的预测能力优于BF和CRPC。

要点

  • PORT后1、3、5、7年OS分别为98%、95%、90%、82%。
  • 时间依赖模型中DM与OS关联最强(HR 6.52,95%CI 4.20-10.1)。
  • 5年DM的c指数为0.78,预测OS能力优于BF和CRPC。

核心结论

  • 5年DM与PORT后较低OS相关,其预后预测能力优于1、3、5或7年BF和CRPC;该中间终点作为OS替代指标需随机试验数据确认。

研究设计与样本

  • 经机构审查委员会批准的多中心回顾性研究,纳入1986至2013年在三级医疗中心连续接受PORT的566例男性,中位随访8.2年。

主要发现

  • PORT后1、3、5、7年OS分别为98%、95%、90%、82%。
  • 控制临床和病理变量后,BF与OS相关(HR 2.32,95%CI 1.45-3.71;p<0.001)。
  • DM与OS相关(HR 6.52,95%CI 4.20-10.1;p<0.001)。
  • CRPC与OS相关(HR 2.47,95%CI 1.56-3.92;p<0.001)。
  • landmark分析中,调整基线协变量后5年DM的c指数最高(0.78),且较仅含基线协变量模型提供的判别力提升最大。

局限性

  • 原文明确述及数据为回顾性性质;研究结果需在前瞻性随机数据中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intermediate clinical endpoints (ICEs) prognostic for overall survival (OS) are needed for men receiving postprostatectomy radiation therapy (PORT) to improve clinical trial design. OBJECTIVE: To identify a potential ICE for men receiving PORT. DESIGN, SETTING, AND PARTICIPANTS: We performed an institutional review board-approved multi-institutional retrospective study of 566 men consecutively treated with PORT at tertiary care centers from 1986 to 2013. The median follow-up was 8.2 yr. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Biochemical failure (BF), distant metastases (DM), and castrate-resistant prostate cancer (CRPC) were evaluated for correlation with OS and assessed as time-dependent variables in a multivariable Cox proportional hazards model and in landmark analyses at 1, 3, 5, and 7 yr after PORT. Cross-validated concordance (c) indices were used to assess model discrimination. RESULTS AND LIMITATIONS: OS at 1, 3, 5, and 7 yr after PORT was 98%, 95%, 90%, and 82%, respectively. In a time-varying model controlling for clinical and pathologic variables, BF (hazard ratio [HR] 2.32, 95% confidence interval [CI] 1.45-3.71; p<0.001), DM (HR 6.52, 95% CI 4.20-10.1; p<0.001), and CRPC (HR 2.47, 95% CI 1.56-3.92; p<0.001) were associated with OS. In landmark analyses, 5-yr DM had the highest c index when adjusting for baseline covariates (0.78), with 5-yr DM also providing the greatest increase in discriminatory power over a model only including baseline covariates. These findings require validation in prospective randomized data. CONCLUSIONS: While limited by the retrospective nature of the data, 5-yr DM is associated with lower OS following PORT, outperforming the prognostic capability of BF and CRPC at 1, 3, 5, or 7 yr after treatment. Confirmation of this ICE as a surrogate for OS is needed from randomized trial data so that it can be incorporated into future clinical trial design. PATIENT SUMMARY: We assessed potential intermediate clinical endpoints prognostic for overall survival in a cohort of men receiving radiotherapy after prostatectomy. We identified the development of metastatic disease within 5 yr after treatment as the strongest predictor of overall survival.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Jackson WC, Suresh K, Tumati V, et al. Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival. Eur Urol. 2018. PMID: 29306514. doi:10.1016/j.eururo.2017.12.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。